

References

- Abebe, E., Demilie, K., Lemmu, B., & Abebe, K. (2020). Female Breast Cancer Patients, Mastectomy-Related Quality of Life: Experience from Ethiopia. *International Journal of Breast Cancer*, 2020, 1–6. <https://doi.org/10.1155/2020/8460374>
- Adam, L. (2020). PENGETAHUAN PENDERITA TUBERKULOSIS PARU TERHADAP KEPATUHAN MINUM OBAT ANTI TUBERKULOSIS. *Jambura Health and Sport Journal*, 2(1), 12–18. <https://ejurnal.ung.ac.id/index.php/jhsj/article/view/4560/1773>
- Amjad, M. T., Kasi, A., & Chidharla, A. (2023). *Cancer Chemotherapy*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK564367/>
- Anbiar, M., Harahap, W., & Lestari, Y. (2024). HUBUNGAN PANDEMI COVID-19 DENGAN STADIUM KANKER PAYUDARA PADA KUNJUNGAN PERTAMA PASIEN KE RUMAH SAKIT DI PADANG. *SENTRI: Jurnal Riset Ilmiah*, 3(7), 3510–3520. <https://ejournal.nusantaraglobal.or.id/index.php/sentri/article/view/3107>
- Andrzejewski, V., Padilha, S. L., Vinícius, J., Diego, F., & Neto, J. Z. (2021). Antineoplásicos Orais: Adesão ao Tratamento e Crenças sobre os Medicamentos. *Revista Brasileira de Cancerologia*, 67(2). <https://doi.org/10.32635/2176-9745.rbc.2021v67n2.1189>
- Anghel, L. A., Farcas, A. M., & Oprean, R. N. (2019). An overview of the common methods used to measure treatment adherence. *Medicine and Pharmacy Reports*, 92(2), 117–122. <https://doi.org/10.15386/mpr-1201>
- Aremu, T. O., Oluwole, O. E., Adeyinka, K. O., & Schommer, J. C. (2022). Medication adherence and compliance: Recipe for improving patient outcomes. *Pharmacy*, 10(5), 1–5. <https://doi.org/10.3390/pharmacy10050106>
- Asamoah-Boaheng, M., Bonsu, K., Farrell, J., Oyet, A., & Midodzi, W. K. (2021). Measuring Medication Adherence in a Population-Based Asthma Administrative Pharmacy Database: A Systematic Review and Meta-Analysis. *Clinical Epidemiology*, Volume 13, 981–1010. <https://doi.org/10.2147/clep.s333534>

- Badan Pengawas Obat dan Makanan. (2020a). *Assessment Report: Palbociclib*. Pom.go.id.
<https://registrasiobat.pom.go.id/en/daftar-produk/assesment-report/DKI1958501501B1>
- Badan Pengawas Obat dan Makanan. (2020b). *Assessment Report: Ribociclib*. Pom.go.id.
<https://registrasiobat.pom.go.id/daftar-produk/assesment-report/65799>
- Badan Pengawas Obat dan Makanan. (2023). *Assessment Report: Abemaciclib*. Pom.go.id.
<https://registrasiobat.pom.go.id/daftar-produk/assesment-report/DKI2073402117A1>
- Bian, X., & Lin, W. (2019). Targeting DNA Replication Stress and DNA Double-Strand Break Repair for Optimizing SCLC Treatment. *Cancers*, 11(9), 1289. <https://doi.org/10.3390/cancers11091289>
- Bonfil, D. (2022). Breast Cancer. In *Breast Cancer* (pp. vii–vii). Exon Publication.
<https://doi.org/10.36255/exon-publications-breast-cancer.foreword>
- Braal, C. L., Jongbloed, E. M., Wilting, S. M., Mathijssen, R. H. J., Koolen, S. L. W., & Jager, A. (2021). Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. *Drugs*, 81(3), 317–331. <https://doi.org/10.1007/s40265-020-01461-2>
- Brody, L. (2020). *Cell Cycle*. National Human Genome Research Institute.
<https://www.genome.gov/genetics-glossary/Cell-Cycle>
- Byers, K. (2021). Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer. *Journal of the Advanced Practitioner in Oncology*, 12(1). <https://doi.org/10.6004/jadpro.2021.12.1.8>
- Byrne, S., Boyle, T., Ahmed, M., Lee, S. H., Benyamin, B., & Hyppönen, E. (2023). Lifestyle, genetic risk and incidence of cancer: a prospective cohort study of 13 cancer types. *International Journal of Epidemiology*, 52(3). <https://doi.org/10.1093/ije/dyac238>
- Cascone, V., Grauer, D. W., & Hosmer, K. (2021). *Evaluation of Inpatient Oral Chemotherapy: An Academic Medical Center Experience*. The Journal of Hematology Oncology Pharmacy. <https://jhonline.com/issue-archive/2020-issues/december-2020-vol-10-no-6/18565:evaluation-of-inpatient-oral-chemotherapy-an-academic-medical-center-experience>

- Cheng, E., Soulos, P. R., Irwin, M. L., Cespedes Feliciano, E. M., Presley, C. J., Fuchs, C. S., Meyerhardt, J. A., & Gross, C. P. (2021). Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. *JAMA Network Open*, 4(12), e2139593–e2139593. <https://doi.org/10.1001/jamanetworkopen.2021.39593>
- Choi, H. Y., & Chang, J. E. (2023). Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. *International Journal of Molecular Sciences*, 24(17), 13618. <https://doi.org/10.3390/ijms241713618>
- Das, S., Kulkarni, S. G., Singh, Y., Kumar, P., & Thareja, S. (2022). Selective Estrogen Receptor Modulators (SERMs) for the treatment of ER+ breast cancer: An overview. *Journal of Molecular Structure*, 1270, 133853–133853. <https://doi.org/10.1016/j.molstruc.2022.133853>
- Deo, S. V. S., Kumar, N., Rajendra, V. K. J., Kumar, S., Bhorawal, S. K., Ray, M., Bhatnagar, S., & Mishra, S. (2021). Palliative Surgery for Advanced Cancer: Clinical Profile, Spectrum of Surgery and Outcomes from a Tertiary Care Cancer Centre in Low-Middle-Income Country. *Indian Journal of Palliative Care*, 27, 281–285. https://doi.org/10.25259/ijpc_399_20
- Devine, F., Edwards, T., & Feldman, S. R. (2018). Barriers to treatment: describing them from a different perspective. *Patient Preference and Adherence*, Volume 12, 129–133. <https://doi.org/10.2147/ppa.s147420>
- Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020). The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. *International Journal of Molecular Sciences*, 21(6). <https://doi.org/10.3390/ijms21061960>
- Dong, P., & Gewirtz, D. A. (2022). Risks and Benefits of Adjuvants to Cancer Therapies. *Frontiers in Oncology*, 12. <https://doi.org/10.3389/fonc.2022.913626>
- Dusetzina, S. B., Besaw, R. J., Whitmore, C. C., Mattingly, T. J., II, Sinaiko, A. D., Keating, N. L., & Everson, J. (2023). Cost-Related Medication Nonadherence and Desire for Medication Cost

- Information Among Adults Aged 65 Years and Older in the US in 2022. *JAMA Network Open*, 6(5), e2314211. <https://doi.org/10.1001/jamanetworkopen.2023.14211>
- El-Nachef, L., Al-Choboq, J., Restier-Veriet, J., & Granzotto, A. (2021). *Human Radiosensitivity and Radiosusceptibility: What Are the Differences?* Nih.gov. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8267933/>
- Elazzazy, S., Al-Ziftawi, N. H., Mohamed Ibrahim, M. I., Bujassoum, S., & Hamad, A. (2024). Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation. *Frontiers in Oncology*, 14. <https://doi.org/10.3389/fonc.2024.1413676>
- FDA. (2023). *FDA expands early breast cancer indication for abemaciclib with endocrine therapy*. FDA. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-early-breast-cancer-indication-abemaciclib-endocrine-therapy>
- Febriani, A., Pujiastuti, F., & Teodhora, T. (2024). Characteristics of Chemotherapy Treatments for Breast Cancer Patients at Bhayangkara Tk.1 Pudsokkes Polri Hospital, Jakarta. *Indonesian Journal of Cancer*, 18(3), 282–288. <https://doi.org/10.33371/ijoc.v18i3.1131>
- Ferlay, J., Ervik, M., & Lam, F. (2024). *Global Cancer Observatory: Cancer Today*. International Agency for Research on Cancer. <https://gco.iarc.who.int/today>
- Fleming, L., Agnew, S., Peddie, N., Crawford, M., Dixon, D., & MacPherson, I. (2022). The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review. *The Breast*, 64, 63–84. <https://doi.org/10.1016/j.breast.2022.04.010>
- Foffano, L., Cucciniello, L., Nicolò, E., Migliaccio, I., Noto, C., Reduzzi, C., Malorni, L., Cristofanilli, M., Gerratana, L., & Puglisi, F. (2024). Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): mechanisms of resistance and where to find them. *The Breast*, 79, 103863–103863. <https://doi.org/10.1016/j.breast.2024.103863>

- Gajarawala, S., & Pelkowski, J. (2020). Telehealth benefits and barriers. *The Journal for Nurse Practitioners*, 17(2), 218–221. <https://doi.org/10.1016/j.nurpra.2020.09.013>
- Gebreyohannes, E. A., Bhagavathula, A. S., Abebe, T. B., Tefera, Y. G., & Abegaz, T. M. (2019). Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital. *Clinical Hypertension*, 25(1). <https://doi.org/10.1186/s40885-018-0104-6>
- George, M., Qureshi, S., Omene, C., Toppmeyer, D., & Ganesan, S. (2021). Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer. *Frontiers in Oncology*, 11. <https://doi.org/10.3389/fonc.2021.693104>
- Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., Jemal, A., & Siegel, R. L. (2022). Breast Cancer Statistics. *CA: A Cancer Journal for Clinicians*, 72(6). <https://doi.org/10.3322/caac.21754>
- Glaviano, A., Song, A., Julia, Y., Yap, K., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Pooyan Makvandi, Geoerger, B., Kulke, M. H., Baird, R. D., Prabhu, J. S., Carbone, D., Pecoraro, C., Boon, D., Sethi, G., Cavalieri, V., Lin, K., & Javidi-Sharifi, N. (2023). PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. *Molecular Cancer*, 22(1). <https://doi.org/10.1186/s12943-023-01827-6>
- Glaviano, A., Wander, S. A., Baird, R. D., Yap, K., Lam, H. Y., Toi, M., Carbone, D., Geoerger, B., Serra, V., Jones, R. H., Ngeow, J., Toska, E., Stebbing, J., Crasta, K., Finn, R. S., Diana, P., Vuina, K., Robertus, R., Surana, U., & Bardia, A. (2024). Mechanisms of Sensitivity and Resistance to CDK4/CDK6 Inhibitors in Hormone Receptor-positive Breast Cancer Treatment. *Drug Resistance Updates*, 76, 101103–101103. <https://doi.org/10.1016/j.drug.2024.101103>
- González-Bueno, J., Sevilla-Sánchez, D., Puigoriol-Juveny, E., Molist-Brunet, N., Codina-Jané, C., & Espauella-Panicot, J. (2021). Factors Associated with Medication Non-Adherence among Patients with Multimorbidity and Polypharmacy Admitted to an Intermediate Care Center.

- International Journal of Environmental Research and Public Health*, 18(18), 9606.
<https://doi.org/10.3390/ijerph18189606>
- Goyal, R. K., Candrilli, S. D., Abughosh, S., Chen, H., Holmes, H. M., & Johnson, M. L. (2024). Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer. *Cancers*, 16(12), 2168–2168.
<https://doi.org/10.3390/cancers16122168>
- Hanna, K., & Mayden, K. (2021). The Use of Real-World Evidence for Oral Chemotherapies in Breast Cancer. *Journal of the Advanced Practitioner in Oncology*, 12(2).
<https://doi.org/10.6004/jadpro.2021.12.2.12>
- Hatta, M., Hanif, E. A., Chin, S.-F., & Neoh, H. (2021). Pathogens and Carcinogenesis: A Review. *Biology*, 10(6), 533. <https://doi.org/10.3390/biology10060533>
- Hermelink, R., Leitzmann, M. F., Markozannes, G., Tsilidis, K., Pukrop, T., Berger, F., Baurecht, H., & Jochem, C. (2022). Sedentary behavior and cancer—an umbrella review and meta-analysis. *European Journal of Epidemiology*, 37(5). <https://doi.org/10.1007/s10654-022-00873-6>
- Huang, J., Zheng, L., Sun, Z., & Li, J. (2022). CDK4/6 inhibitor resistance mechanisms and treatment strategies . *International Journal of Molecular Medicine*, 50(4).
<https://doi.org/10.3892/ijmm.2022.5184>
- Husna, N., Sugiyono, S., & Yunilistianingsih, Y. (2023). Analisis Pengetahuan, Kepatuhan, dan Outcome Klinis Pasien Hipertensi di Puskesmas Jetis Yogyakarta. *JURNAL ILMU KEFARMASIAN INDONESIA*, 21(1), 1. <https://doi.org/10.35814/jifi.v21i1.1100>
- IARC. (2018). *Diet, activity and cancer*. WCRF International.
<https://www.wcrf.org/diet-activity-and-cancer/>
- Institute For Health Metrics and Evaluation. (2019). *The Lancet: Latest global disease estimates reveal perfect storm of rising chronic diseases and public health failures fuelling COVID-19 pandemic* / The Institute for Health Metrics and Evaluation. www.healthdata.org.

<https://www.healthdata.org/news-events/newsroom/news-releases/lancet-latest-global-disease-estimates-reveal-perfect-storm>

- Iranzo, P., Callejo, A., Assaf, J. D., Molina, G., Lopez, D. E., Garcia-Illescas, D., Pardo, N., Navarro, A., Martinez-Marti, A., Cedres, S., Carbonell, C., Frigola, J., Amat, R., & Felip, E. (2022). Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. *Frontiers in Medicine*, 9. <https://doi.org/10.3389/fmed.2022.875974>
- Jacobs, F., Agostinetto, E., Solferino, A., Torrisi, R., Masci, G., Santoro, A., & Sanctis, R. (2023). Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib. *Journal of Clinical Medicine*, 12(5), 1775–1775. <https://doi.org/10.3390/jcm12051775>
- Jacobs, J. M., Ream, M. E., Pensak, N., Nisotel, L. E., Fishbein, J. N., MacDonald, J. J., Buzaglo, J., Lennes, I. T., Safren, S. A., Pirl, W. F., Temel, J. S., & Greer, J. A. (2019). Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life. *Journal of the National Comprehensive Cancer Network*, 17(3), 221–228. <https://doi.org/10.6004/jnccn.2018.7098>
- Jamnasi, J. (2021). RESPON BAIK KOMBINASI CDK 4/6 INHIBITOR DAN AROMATASE INHIBITOR DENGAN RADIOTERAPI KONKUREN PADA KANKER PAYUDARA STADIUM LANJUT TIPE LUMINAL. *Jurnal Kedokteran Methodist*, 14(2), 64–68. <https://ejurnal.methodist.ac.id/index.php/jkm/article/view/741>
- Janowska, S., Holota, S., Lesyk, R., & Wujec, M. (2024). Aromatase Inhibitors as a Promising Direction for the Search for New Anticancer Drugs. *Molecules*, 29(2), 346–346. <https://doi.org/10.3390/molecules29020346>
- Kalinsky, K., Bianchini, G., Hamilton, E., Graff, S. L., Park, K. H., Jeselsohn, R., Martin, M., Layman, R. M., Hurvitz, S. A., Sammons, S., Kaufman, P. A., Muñoz, M., Lai, J.-I., Knoderer, H., Sandoval, C., Chawla, A. R., Nguyen, B., Zhou, Y., Ravenberg, E., & Litchfield, L. M. (2024). Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition:

- Results from the Phase III postMONARCH Trial. *Journal of Clinical Oncology*.
<https://doi.org/10.1200/jco-24-02086>
- Katta, B., Vijayakumar, C., Dutta, S., Biswajit Dubashi, & Prasad, V. (2023). The Incidence and Severity of Patient-Reported Side Effects of Chemotherapy in Routine Clinical Care: A Prospective Observational Study. *Cureus*, 15(4). <https://doi.org/10.7759/cureus.38301>
- Kawaguchi, K., Maeshima, Y., Ishiguro, H., Yamagami, K., Takahara, S., Suwa, H., Torii, M., Nagai, S., Sagara, Y., Tsuji, W., Yamashiro, H., Kotake, T., Fukuda, S., Saito, K., Yamamoto, Y., Kataoka, M., Himoto, Y., Yonezawa, A., Fukui, Y., & Nakamura, Y. (2023). Alteration of gut microbiota signatures and its association with diarrhea during abemaciclib treatment: A multicenter prospective cohort study . *Cancer Research*, 83(5_Supplement), P2-2607-P226-07. <https://doi.org/10.1158/1538-7445.sabcs22-p2-26-07>
- Kedrzycki, M. S., Elson, D. S., & Leff, D. R. (2022). Guidance in breast-conserving surgery: tumour localization versus identification. *British Journal of Surgery*, 110(8), 920–922. <https://doi.org/10.1093/bjs/znac409>
- Kementerian Kesehatan Republik Indonesia. (2016). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016 tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016–2019*. Jakarta: Kementerian Kesehatan RI
- Koka, K., Verma, A., Dwarakanath, B. S., & Papineni, R. V. (2022). Technological Advancements in External Beam Radiation Therapy (EBRT): An Indispensable Tool for Cancer Treatment. *Cancer Management and Research*, Volume 14, 1421–1429. <https://doi.org/10.2147/cmar.s351744>
- Kolasinski, N., Pasman, E. A., Nylund, C. M., Reeves, P. T., Brooks, D. I., Lescouflair, K. G., & Min, S. B. (2024). Improved Outcomes in Eosinophilic Esophagitis with Higher Medication Possession Ratio. *Medicines*, 11(4), 8–8. <https://doi.org/10.3390/medicines11040008>
- Konstantinou, P., Kassianos, A. P., Georgiou, G., Panayides, A., Papageorgiou, A., Almas, I., Wozniak, G., & Karekla, M. (2020). Barriers, facilitators, and interventions for medication adherence across chronic conditions with the highest non-adherence rates: a scoping review with

- recommendations for intervention development. *Translational Behavioral Medicine*, 10(6).
<https://doi.org/10.1093/tbm/ibaa118>
- Kvarnström, K., Airaksinen, M., & Liira, H. (2018). Barriers and facilitators to medication adherence: a qualitative study with general practitioners. *BMJ Open*, 8(1).
<https://doi.org/10.1136/bmjopen-2016-015332>
- Kvarnström, K., Westerholm, A., Airaksinen, M., & Liira, H. (2021). Factors contributing to medication adherence in patients with a chronic condition: A scoping review of qualitative research. *Pharmaceutics*, 13(7). <https://doi.org/10.3390/pharmaceutics13071100>
- Lawrenti, H. (2022). Penghambat CDK4/6 untuk Terapi Kanker Payudara. *Cermin Dunia Kedokteran*, 49(5), 284–289. <https://doi.org/10.55175/cdk.v49i5.235>
- Li, L., Shan, T., Zhang, D., & Ma, F. (2024). Nowcasting and forecasting global aging and cancer burden: analysis of data from the GLOBOCAN and Global Burden of Disease Study. *Journal of the National Cancer Center*, 4(3), 223–232. <https://doi.org/10.1016/j.jncc.2024.05.002>
- Lin, W., Zeng, Y., Weng, L., Yang, J., & Zhuang, W. (2024). Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study. *BMC Pharmacology and Toxicology*, 25(1).
<https://doi.org/10.1186/s40360-024-00770-6>
- Ling, S. P., Ming, L. C., Dhaliwal, J. S., Gupta, M., Ardianto, C., Goh, K. W., Hussain, Z., & Shafqat, N. (2022). Role of Immunotherapy in the Treatment of Cancer: A Systematic Review. *Cancers*, 14(21), 5205. <https://doi.org/10.3390/cancers14215205>
- Łukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanislawek, A. (2021). Breast cancer—epidemiology, Risk factors, classification, Prognostic markers, and Current Treatment Strategies—an Updated Review. *Cancers*, 13(17). <https://doi.org/10.3390/cancers13174287>
- Maeda, A., Irie, K., Hashimoto, N., Fukushima, S., Ando, H., Okada, A., Ebi, H., Kajita, M., Iwata, H., & Sawaki, M. (2021). Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a

- preliminary report. *Investigational New Drugs*, 39(1), 272–277.
<https://doi.org/10.1007/s10637-020-00994-3>
- Martins, V., Jesus, M., Pereira, L., Monteiro, C., Duarte, A. P., & Morgado, M. (2023). Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System. *Pharmaceuticals*, 16(10), 1340–1340.
<https://doi.org/10.3390/ph16101340>
- Mayer, E. L., Dueck, A. C., Martin, M., Rubovszky, G., Burstein, H. J., Bellet-Ezquerria, M., Miller, K. D., Zdenkowski, N., Winer, E. P., Pfeiler, G., Goetz, M., Ruiz-Borrego, M., Anderson, D., Nowecki, Z., Loibl, S., Moulder, S., Ring, A., Fitzal, F., Traina, T., & Chan, A. (2021). Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. *The Lancet Oncology*, 22(2), 212–222.
[https://doi.org/10.1016/S1470-2045\(20\)30642-2](https://doi.org/10.1016/S1470-2045(20)30642-2)
- Mayer, E. L., Ren, Y., Wagle, N., Mahtani, R., Ma, C., DeMichele, A., Cristofanilli, M., Meisel, J., Miller, K. D., Abdou, Y., Riley, E. C., Qamar, R., Sharma, P., Reid, S., Sinclair, N., Faggen, M., Block, C. C., Ko, N., Partridge, A. H., & Chen, W. Y. (2024). PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer. *Journal of Clinical Oncology*, 42(17), 2050–2060. <https://doi.org/10.1200/jco.23.01940>
- Mee, T., Kirkby, N. F., Noémie Defourny, Kirkby, K. J., & Burnet, N. G. (2023). The use of radiotherapy, surgery and chemotherapy in the curative treatment of cancer: results from the FORTY (Favourable Outcomes from RadioTherapY) project. *British Journal of Radiology*.
<https://doi.org/10.1259/bjr.20230334>
- Mercadante, A. A., & Kasi, A. (2023, August 14). *Genetics, Cancer Cell Cycle Phases*. National Library of Medicine; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK563158/>

- Miller, W. R., Bartlett, J., Brodie, A. M. H., Brueggemeier, R. W., di Salle, E., Lønning, P. E., Llombart, A., Maass, N., Maudelonde, T., Sasano, H., & Goss, P. E. (2008). Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter? *The Oncologist*, 13(8), 829–837. <https://doi.org/10.1634/theoncologist.2008-0055>
- Min, H., & Lee, H. (2022). Molecular targeted therapy for anticancer treatment. *Experimental & Molecular Medicine*, 54(10), 1670–1694. <https://doi.org/10.1038/s12276-022-00864-3>
- Mir, T. H. (2023). Adherence Versus Compliance. *HCA Healthcare Journal of Medicine*, 4(2). <https://doi.org/10.36518/2689-0216.1513>
- Mittal, A., Valiente, C. M., Tamimi, F., Schlam, I., Sammons, S., Tolaney, S. M., & Tarantino, P. (2023). Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. *Cancers*, 15(7), 2015–2015. <https://doi.org/10.3390/cancers15072015>
- Mohanty, S. S., & Mohanty, P. K. (2019). Obesity as potential breast cancer risk factor for postmenopausal women. *Genes & Diseases*, 8(2). <https://doi.org/10.1016/j.gendis.2019.09.006>
- Montégut, L., López-Otín, C., & Kroemer, G. (2024). Aging and cancer. *Molecular Cancer*, 23(1). <https://doi.org/10.1186/s12943-024-02020-z>
- Moura, T., Caramelo, O., Silva, I., Silva, S., Gonçalo, M., Portilha, M. A., Moreira, J. N., Gil, A. M., Laranjeira, P., & Paiva, A. (2025). Early-Stage Luminal B-Like Breast Cancer Exhibits a More Immunosuppressive Tumor Microenvironment than Luminal A-Like Breast Cancer. *Biomolecules*, 15(1), 78–78. <https://doi.org/10.3390/biom15010078>
- Murad, B., Reis, P., Marinho, A., Comini, A. C., Xavier, D., Pessoa, B., Raheem, F., Ernst, B., Mina, L., & Batalini, F. (2024). QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. *JNCI Cancer Spectrum*, 8(5). <https://doi.org/10.1093/jncics/pkae078>

- Nagamine, Y., Shobugawa, Y., Sasaki, Y., Takagi, D., Fujiwara, T., Yu Par Khin, Nozaki, I., & Shirakura, Y. (2023). Associations between socioeconomic status and adherence to hypertension treatment among older adults in urban and rural areas in Myanmar: a cross-sectional study using baseline data from the JAGES in Myanmar prospective cohort study. *BMJ Open*, 13(1). <https://doi.org/10.1136/bmjopen-2022-065370>
- National Cancer Institute. (2017). *Common Terminology Criteria for Adverse Events*. Ctep.cancer.gov. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60
- National Cancer Institute. (2021). *Age and Cancer Risk*. National Cancer Institute; Cancer.gov. <https://www.cancer.gov/about-cancer/causes-prevention/risk/age>
- National Cancer Institute. (2024). *BRCA Mutations: Cancer Risk & Genetic Testing*. National Cancer Institute. <https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet>
- Norman, H., Lee, K. T., Stearns, V., Alcorn, S. R., & Mangini, N. (2022). Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature. *Clinical Breast Cancer*, 22(1), e65–e73. <https://doi.org/10.1016/j.clbc.2021.07.013>
- Ohshika, S., Saruga, T., Ogawa, T., Ono, H., & Ishibashi, Y. (2021). Distinction between benign and malignant soft tissue tumors based on an ultrasonographic evaluation of vascularity and elasticity. *Oncology Letters*, 21(4). <https://doi.org/10.3892/ol.2021.12542>
- Oliveira, P. A., & Faustino-Rocha, A. I. (2023). Chemical Carcinogens. *Springer EBooks*, 1–23. https://doi.org/10.1007/978-3-030-80962-1_121-1
- Onesti, C. E., & Jerusalem, G. (2020). CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. *Expert Review of Anticancer Therapy*, 21(3), 283–298. <https://doi.org/10.1080/14737140.2021.1852934>
- Organization, W. H. (2003). Adherence to long-term therapies : evidence for action. In *iris.who.int*. World Health Organization. <https://iris.who.int/handle/10665/42682>

- Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L. E., Gómez-Valles, F. O., & Ramírez-Valdespino, C. A. (2022, August 6). *Subtypes of Breast Cancer* (H. N. Mayrovitz, Ed.). PubMed; Exon Publications. <https://www.ncbi.nlm.nih.gov/books/NBK583808/>
- Oswald, L. B., Arredondo, B., Kadono, M., Martinez-Tyson, D., Meade, C. D., Penedo, F., Antoni, M. H., Soliman, H., Costa, R. L. B., & Jim, H. S. L. (2021). A mixed-methods study of cyclin-dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers. *Cancer Medicine*. <https://doi.org/10.1002/cam4.4055>
- Panahi, S., Rath, N., Hurley, J., Sundrud, J., Lucero, M., & Kamimura, A. (2022). Patient Adherence to Health Care Provider Recommendations and Medication among Free Clinic Patients. *Journal of Patient Experience*, 9, 237437352210775. <https://doi.org/10.1177/23743735221077523>
- Patel, A. (2020). Benign vs Malignant Tumors. *JAMA Oncology*, 6(9). <https://doi.org/10.1001/jamaoncol.2020.2592>
- Patel, H. K., & Bihani, T. (2018). Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. *Pharmacology & Therapeutics*, 186, 1–24. <https://doi.org/10.1016/j.pharmthera.2017.12.012>
- Patro, J., Sheela, E., Srinavva, M., Jyothika, A., & Sailaja, M. (2023). A review on pathophysiology of breast cancer. *International Journal of Pharmaceutical Sciences and Drug Analysis*, 3(1), 94–97. <https://www.pharmacyjournal.info/archives/2023.v3.i1.B.52>
- Ponti, F., Santoro, A., Mercatelli, D., Gasperini, C., Conte, M., Martucci, M., Sangiorgi, L., Franceschi, C., & Bazzocchi, A. (2020). Aging and Imaging Assessment of Body Composition: From Fat to Facts. *Frontiers in Endocrinology*, 10(861). <https://doi.org/10.3389/fendo.2019.00861>
- Rastogi, P., O'Shaughnessy, J., Martín, M., Boyle, F. M., Cortés, J., Rugo, H. S., Goetz, M. P., Hamilton, E., Huang, C., Senkus, E., Tryakin, A. A., Çiçin, İ., Testa, L., Neven, P., Huober, J., Shao, Z., Wei, R., André, V., Muñoz, M., & Antonio, B. (2024). Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim

- Analysis, Including 5-Year Efficacy Outcomes. *Journal of Clinical Oncology*.
<https://doi.org/10.1200/jco.23.01994>
- Reimann, L., Preiss, H., Müller, J., Huber, P., Mayer, L., Langleben, D., Ulrich, S., & Lichtblau, M. (2025). Medication adherence and clinical outcome in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension. *BMJ Open Respiratory Research*, 12(1). <https://doi.org/10.1136/bmjresp-2024-003023>
- Rugo, H. S., Huober, J., García-Sáenz, J. A., Masuda, N., Sohn, J. H., Andre, V. A. M., Barriga, S., Cox, J., & Goetz, M. (2020). Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. *The Oncologist*.
<https://doi.org/10.1002/onco.13531>
- Sanctis, R. D., Tiberio, P., Jacobs, F., Gaudio, M., Benvenuti, C., Giordano, L., Torrisi, R., Zambelli, A., Pozzi, C., Penna, G., Santoro, A., & Rescigno, M. (2024). Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer. *The Oncologist*, 29(9).
<https://doi.org/10.1093/oncolo/oyae101>
- Seetharama, S. D., Srinivas, A., Pawar, V. B., Gupta, B. S., & Palaksha, S. (2024). Assessment of Medication Adherence and Common Non-Adherence: A Routinely Overlooked Hurdle. *International Journal of Pharmaceutical Investigation*, 14(4), 1079–1084.
<https://doi.org/10.5530/ijpi.14.4.118>
- Shah, K. K., Touchette, D. R., & Marrs, J. C. (2023). Research and scholarly methods: Measuring medication adherence. *Journal of the American College of Clinical Pharmacy*, 6(4).
<https://doi.org/10.1002/jac5.1771>
- Shanbari, N., Alharthi, A. I., Bakry, S. M., Alzahrani, M., Alhijjy, M. M., Mirza, H., Almutairi, M., & Ekram, S. (2023). Knowledge of Cancer Genetics and the Importance of Genetic Testing: A Public Health Study. *Cureus*, 15(8). <https://doi.org/10.7759/cureus.43016>

- Shuel, S. L. (2022). Targeted cancer therapies. *Canadian Family Physician*, 68(7), 515–518.
<https://doi.org/10.46747/cfp.6807515>
- Sinks, A. L., Holck, H. W., McGrath, L. G., Zeng, L., Gaston, K. E., Riggs, S. B., Matulay, J. T., Clark, P. E., & Roy, O. P. (2024). Impact of Socioeconomic Status on Patient Adherence in Managing Renal Masses. *Urology Practice*, 11(4), 736–744. <https://doi.org/10.1097/UPJ.0000000000000565>
- Skolariki, A., D’Costa, J., Little, M., & Lord, S. (2022). Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. *Exploration of Targeted Anti-Tumor Therapy*, 172–199. <https://doi.org/10.37349/etat.2022.00078>
- Slamon, D., Lipatov, O., Nowecki, Z., McAndrew, N., Kukiela-Budny, B., Stroyakovskiy, D., Yardley, D. A., Huang, C.-S., Fasching, P. A., Crown, J., Bardia, A., Chia, S., Im, S.-A., Ruiz-Borrego, M., Loi, S., Xu, B., Hurvitz, S., Barrios, C., Untch, M., & Moroosse, R. (2024). Ribociclib plus Endocrine Therapy in Early Breast Cancer. *The New England Journal of Medicine*, 390(12), 1080–1091. <https://doi.org/10.1056/nejmoa2305488>
- Smith, J. N., Gaither, K. A., & Pande, P. (2022). Competitive Metabolism of Polycyclic Aromatic Hydrocarbons (PAHs): An Assessment Using In Vitro Metabolism and Physiologically Based Pharmacokinetic (PBPK) Modeling. *International Journal of Environmental Research and Public Health*, 19(14), 8266. <https://doi.org/10.3390/ijerph19148266>
- Sperber, C., Samarasinghe, S. R., & Lomax, G. P. (2017). An upper and lower bound of the Medication Possession Ratio. *Patient Preference and Adherence*, Volume 11, 1469–1478. <https://doi.org/10.2147/ppa.s136890>
- Spring, L. M., Wander, S. A., Andre, F., Moy, B., Turner, N. C., & Bardia, A. (2020). Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. *Lancet*, 395(10226), 817–827. [https://doi.org/10.1016/S0140-6736\(20\)30165-3](https://doi.org/10.1016/S0140-6736(20)30165-3)
- Stanford Medicine. (2019). *Stanford Health Care*. [Stanfordhealthcare.org](https://stanfordhealthcare.org).
<https://stanfordhealthcare.org/medical-treatments/c/cancer-surgery/types.html>

- Tagliaferri, B., Mollica, L., Palumbo, R., Leli, C., Malovini, A., Terzaghi, M., Quaquarelli, E., Teragni, C., Maccarone, S., Premoli, A., & Sottotetti, F. (2023). Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR+/HER2– breast cancer treated with CDK4/6 inhibitors and endocrine therapy. *Drugs in Context*, 12, 1–14. <https://doi.org/10.7573/dic.2023-1-7>
- Tang, K. L., Quan, H., & Rabi, D. M. (2017). Measuring medication adherence in patients with incident hypertension: a retrospective cohort study. *BMC Health Services Research*, 17(1). <https://doi.org/10.1186/s12913-017-2073-y>
- Tekade, M., Pingale, P. L., Wani, S. P., Rajpoot, K., Sreeharsha, N., Deshpande, M., Tekade, R. K., & Sharma, M. C. (2023). Clinical detoxification of the body from chemical toxicants. *Elsevier EBooks*, 469–505. <https://doi.org/10.1016/b978-0-443-15840-7.00012-9>
- Teomete, M., Cabuk, D., Korkmaz, T., Seber, S., Ozturk, O., Aver, B., Karaalp, A., & Basaran, G. (2024). Recommendations for cyclin-dependent kinase 4/6 inhibitor treatments in the context of co-morbidity and drug interactions. *Oncology Letters*, 27(4). <https://doi.org/10.3892/ol.2024.14278>
- Thierry-Chef, I., Timmermann, B., Journy, N., Bernier, M.-O., McNally, R., Dabin, J., Brualla, L., Haghdoust, S., Sarukhan, A., Haustermans, K., Wit, I. D., Isebaert, S., Lassen-Ramshad, Y., Henriksen, L. T., Høyer, M., Toussaint, L., Boissonnat, G., Thariat, J., Demoor-Goldschmidt, C., & Haddy, N. (2023). Health effects of ionising radiation in paediatrics undergoing either cardiac fluoroscopy or modern radiotherapy (The HARMONIC project). *EPJ Nuclear Sciences & Technologies*, 9, 22. <https://doi.org/10.1051/epjn/2023009>
- Thurston, D., & Pysz, I. (2021). *Chemistry and Pharmacology of Anticancer Drugs*. CRC Press.
- Tomida, J., Wasa, C., Jacobsen, R., Joo, J., Fujii, A., & Iihara, N. (2024). Associated Factors and Causes of Chronic Disease Medication Oversupply. *Biological and Pharmaceutical Bulletin*, 47(12), 2032–2040. <https://doi.org/10.1248/bpb.b24-00551>

- Turcu-Stiolica, A., Naidin, M. S., Gheorman, V., Aldea, M., Dumitrescu, E. A., Volovat, S. R., Median, D. M., & Lungulescu, C. V. (2024). PCR111 Real-World Evidence on Adherence to the First CDK 4/6 Inhibitor (Palbociclib) in Breast Cancer Patients From Romania. *Value in Health*, 27(6), S316–S317. <https://doi.org/10.1016/j.jval.2024.03.1990>
- Turcu-Stiolica, A., Udristoiu, I., Subtirelu, M.-S., Gheorman, V., Aldea, M., Dumitrescu, E. A., Volovat, S. R., Median, D. M., & Lungulescu, C. V. (2024). Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania. *Frontiers in Pharmacology*, 15. <https://doi.org/10.3389/fphar.2024.1345482>
- Vaidya, J. S. (2021). Principles of cancer treatment by radiotherapy. *Surgery (Oxford)*, 39(4), 193–201. <https://doi.org/10.1016/j.mpsur.2021.02.002>
- Wang, X., Zhao, S., Xin, Q., Zhang, Y., Wang, K., & Li, M. (2024). Recent progress of CDK4/6 inhibitors' current practice in breast cancer. *Cancer Gene Therapy*, 1–9. <https://doi.org/10.1038/s41417-024-00747-x>
- West, M., Kaempf, A., Goodyear, S., Kartika, T., Ribkoff, J., & Mitri, Z. I. (2021). Real-world analysis of disease progression after CDK 4/6 inhibitor (CDKi) therapy in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC). *Journal of Clinical Oncology*, 39(15). https://doi.org/10.1200/jco.2021.39.15_suppl.e13030
- Widiana, I. K., & Irawan, H. (2020). Clinical and Subtypes of Breast Cancer in Indonesia. *Asian Pacific Journal of Cancer Care*, 5(4), 281–285. <https://doi.org/10.31557/apjcc.2020.5.4.281-285>
- World Health Organization. (2003). *Adherence to long-term therapies : evidence for action*. Geneva World Health Organization.
- World Health Organization. (2021). *Cancer Today*. Gco.iarc.who.int. <https://gco.iarc.fr/today/en>
- World Health Organization. (2022). *Cancer*. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/cancer>

- Xu, X., Pan, X., Wang, T., Wang, J., Yang, B., He, Q., & Ding, L. (2020). Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies. *Acta Pharmacologica Sinica*, 42(2), 171–178. <https://doi.org/10.1038/s41401-020-0416-4>
- Xue, Y. (2024). Strategy of combining CDK4/6 inhibitors with other therapies and mechanisms of resistance. *International Journal of Clinical and Experimental Pathology*, 17(7), 189–207. <https://doi.org/10.62347/hgni4903>
- Yang, L., Xue, J., Yang, Z., Wang, M., Yang, P., Dong, Y., He, X., Bao, G., & Peng, S. (2021). Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2– advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. *Annals of Palliative Medicine*, 10(5), 5590–5599. <https://doi.org/10.21037/apm-21-1096>
- Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, N., Behl, T., Jha, S. K., & Tang, H. (2023). Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. *Advancements in Clinical Aspects of Targeted Therapy and Immunotherapy in Breast Cancer*, 22(1). <https://doi.org/10.1186/s12943-023-01805-y>
- Yoon, S., Kwan, Y. H., Yap, W. L., Lim, Z. Y., Phang, J. K., Loo, Y. X., Aw, J., & Low, L. L. (2023). Factors influencing medication adherence in multi-ethnic Asian patients with chronic diseases in Singapore: A qualitative study. *Frontiers in Pharmacology*, 14. <https://doi.org/10.3389/fphar.2023.1124297>